Top NYC, NY Social Impact Companies With Best Stability & Growth (268)

Strong Revenue Growth: Recent results show Hinge’s direct revenue up 28% year over year in Q1 2026, following a 39% rise in 2024 to $550.4 million and a further step-up to about $691 million in 2025.

Market Expansion: Expansion into Europe and Latin America is gaining traction, with international revenue reaching 31% of total in 2024 (up from 18%) and launches in Mexico and Brazil attaining the No. 2 download position by late 2025.

Resilient & Sustainable Growth: Trust and safety investments such as Face Check reduced interactions with bad actors by 20–30% with minimal revenue impact, supporting sustained engagement and monetization.

Investor Backing & Capital Strength: Capital raises and valuation step‑ups are prominent, including a $100M Series D in July 2024 at a reported $2.3B valuation to fund expansion into Medicare Advantage and Medicaid. Independent coverage and company materials corroborate the round and use of proceeds.

Market Expansion: Nationwide availability (all 50 states + D.C.) and moves into Medicare Advantage (targeted 51 markets by end‑2024) with Medicaid launches planned for 2025 broaden the addressable market. Company updates indicate these government lines are now active in select states.

Strategic Partnerships: Payer connectivity has accelerated from roughly 40 to 70+ plans with preferred‑network status at major carriers, and revenue scales with completed sessions rather than sign‑ups. These relationships underpin growing patient access and utilization.

Strong Hiring & Retention: Active recruiting is evident with 20+ open roles on Indeed across multiple states and functions, alongside a LinkedIn size band of 51–200 and recent activity signaling team buildout. Role postings span therapists, a remote RN health advocate, and operations/partnerships positions, indicating capacity expansion.

Market Expansion: Medicare-covered virtual therapy is marketed across all 50 states with state-by-state pages and booking via channels like Zocdoc, pointing to an enlarging go-to-market footprint. Site and blog updates through 2025–2026 and a market-launch role (e.g., Philadelphia) further support ongoing geographic growth.

Strategic Partnerships: A publicly announced collaboration with Advanced Nursing & Home Care and recent LinkedIn partnership/event posts suggest growing referral networks. These signals align with efforts to embed within senior-care ecosystems to broaden distribution.

Strategic Partnerships: Government and ecosystem collaborations, including statewide programs (e.g., Iowa HHS and other state-backed access initiatives), lower switching costs and widen distribution. Company materials describe these programs as meaningful adoption accelerators across multiple states.

Innovation-Driven Growth: A weekly changelog citing “865 updates in the last 12 months,” with new CRM, billing, communication, and AI features through July 2026, indicates sustained product velocity. This active shipping cadence supports scale and ongoing customer adoption.

Market Expansion: Company pages highlight 5,000+ programs and 500,000+ users and feature a July 2026 story of a multi‑site operator standardizing across 21 locations, pointing to broader adoption. External indicators like a 51–200 employee band on LinkedIn and visible hiring further suggest ongoing scaling.

Investor Backing & Capital Strength: Recent financing includes a $12M Series B closed on December 4, 2023, explicitly earmarked for expansion and product development. This fresh capital, alongside prior funding, signals resources to scale operations.

Strong Revenue Growth: Public statements since 2022 cite multi-fold increases in revenue and client count, and current materials reference “tens of millions in revenue.” Together with growing placement volumes, this indicates sustained revenue expansion.

Market Expansion: Stated plans include scaling to the largest U.S. financial institutions and expanding into earlier-stage delinquency workflows beyond post charge-off collections. The company also notes that creditors place more volume with it each year, suggesting deepening penetration.

Investor Backing & Capital Strength: Recent funding activity—including a reported portion of a $30M+ round in July 2026 alongside a $28.1M Series B in 2023—signals strengthened runway to support operations and selective scaling. This momentum points to renewed capacity to invest in growth after a difficult 2025.

Market Expansion: A multi-state footprint with launches and active operations across Florida, Michigan, Ohio, Virginia, and Washington reflects continued geographic reach. Active job postings and partner-facing materials further indicate ongoing expansion activity aimed at Medicaid/Medicare populations with SMI.

Strategic Partnerships: Payer-facing positioning and reported collaborations with large platforms (e.g., Carelon Behavioral Health) show ongoing engagement with Medicaid managed care organizations. These arrangements suggest continued commercial traction in value-based models for SMI populations.

Investor Backing & Capital Strength: Ownership by KIRKBI, which acquired BrainPOP in 2022, provides long-term capital and a mandate to invest and expand. Communications around the deal describe continued independence with resources to drive the next phase of growth.

Product Line Growth: The company has expanded from core K–8 videos into BrainPOP Science for grades 6–8 and continues to roll out updates. Earning ESSA Level 3 (“promising evidence”) in 2026 supports district purchasing and broadens adoption.

Strong Market Position & Advantage: At acquisition, the company reported presence in over two‑thirds of U.S. districts and an estimated 25 million students reached annually. This installed base and distribution create a platform for ongoing expansion.

Innovation-Driven Growth: AI site selection and AI patient pre-screening launched in 2025–2026 are described as streamlining screening and improving enrollment efficiency. These releases signal a deepening product footprint aligned to faster activation and more representative enrollment.

Strategic Partnerships: A 2025 data partnership with RealTime eClinical Solutions and highlighted work with major pharma logos are presented as ecosystem validation and traction. These collaborations integrate site performance data and extend marketplace reach.

Market Expansion: The network is portrayed as growing from about 5,500 to 6,000+ research sites across 50+ countries into 2026. Sponsor materials and industry posts indicate steady expansion of marketplace breadth.

Strong Revenue Growth: Recent parent disclosures indicate Brigit’s revenue increased sharply year over year into early 2026, with double‑digit gains in both paying subscribers and ARPU. Quarterly materials consistently frame the segment as a growth engine inside Upbound.

Profitability: Q1 2026 results show positive net earnings and a step‑up in adjusted EBITDA, pointing to profitable expansion rather than growth at any cost. Management commentary highlights margin performance alongside top‑line momentum.

Investor Backing & Capital Strength: The acquisition by Upbound for up to $460 million and ongoing inclusion of Brigit metrics in guidance and earnings decks signal strong sponsor support and access to resources. Deal materials and projections reflect confidence in continued expansion.

Investor Backing & Capital Strength: Significant late-stage financing, including an $88M Series C (April 2024) and a $150M Series D (March 2026) at a reported ~$3B valuation, is presented as fuel for continued scale. These rounds are explicitly tied to expanding product capabilities, the provider network, and payer/employer channels.

Strategic Partnerships: Expanded collaborations are highlighted, including a June 2026 research partnership with Stanford and broad access via 125+ insurer relationships, with added employer and health‑system programs (e.g., EAP‑to‑insurance continuity, Amazon, Circle Medical). These linkages signal deeper distribution and credibility across stakeholders.

Market Expansion: Operational reach appears to be widening through national payer coverage (including Medicare/Medicaid), employer routes, and health‑system integrations alongside a provider network cited around 26,000. Utilization markers such as 7M visits in 2025 and active hiring/office expansion indicate scaling across markets.

Investor Backing & Capital Strength: Recent financing includes a June 2024 seed and an October 2025 $15.5M Series A led by Costanoa with Town Hall Ventures and Khosla, positioned to fund hiring, product, and market expansion. Public investor and media materials describe this capital as intended to scale operations and partnerships.

Market Expansion: Operations are described as growing beyond New York into New Jersey and Ohio, with compliance entities in multiple states and localized, multilingual school pages signaling multi‑district deployment. District approvals and company updates point to a widening on‑the‑ground footprint.

Strategic Partnerships: Public district materials (e.g., Millville Public Schools and Upper Deerfield Township in NJ) announce Marble programs, indicating active school partnerships. Company communications highlight a school‑centered model built specifically for schools, reinforcing this partnership‑led growth.

Investor Backing & Capital Strength: A $30M Series B led by Andreessen Horowitz, bringing total funding to $50M, signals ample expansion capital and strong sponsor conviction. Public launch timing and subsequent scaling activity align with use of growth capital.

Market Expansion: The company cites serving 500+ providers across all 50 states and is broadening from ABA into PT and ENT/Allergy, indicating growing geographic and specialty reach. Plans to extend into home health, long-term care, and substance use disorders further underscore an active expansion strategy.

Strategic Partnerships: A formal partnership with Flychain announced in October 2025 reflects ecosystem traction and an expanding go-to-market footprint. Related claims about scale in ABA billing suggest influence within its initial beachhead vertical.

Market Expansion: Operations are described across numerous U.S. cities and key European hubs (Dublin, Paris, London, Berlin), indicating a broadened geographic footprint beyond a single‑market provider. Materials also reference global pickup capability across regions, signaling scale beyond a local service.

Product Line Growth: Recent updates highlight expanded Device Retrievals to cover more device types and packaging options. A software‑enabled lifecycle platform with a SaaS app, API, and unified data model points to ongoing broadening of the offering.

Strategic Partnerships: Enterprise logos and customer mentions (e.g., Instacart, Lyft, Qualtrics, X) and a California public‑sector pilot indicate embedded institutional relationships. Third‑party materials such as an ESG report from Ping Identity also reference active programs tied to Revivn.

Product Line Growth: Pharma Direct expanded rapidly, rising 41% in 2025 and 82% year over year to $52.2M in Q1 2026, while subscriptions grew 16% year over year in Q1 2026. New offerings such as Employer Direct and GoodRx Companion indicate continued build‑out of recurring and manufacturer‑aligned products.

Strategic Partnerships: Manufacturer‑sponsored pricing programs and expanded partnerships underpinned Pharma Direct’s surge, including GLP‑1 launches and broader retail coverage. The company also reported tripling its retail e‑commerce footprint and an 83% quarter‑over‑quarter jump in Rx Marketplace order volume tied to new partnerships.

Strong Market Position & Advantage: The platform is widely regarded as a leader in U.S. prescription savings, with acceptance at 70,000+ pharmacies and usage by nearly 30 million consumers and over one million healthcare professionals annually. This scale and reach reinforce its competitive position even as the business mix shifts.

Strong Market Position & Advantage: Independent trade coverage and company materials consistently describe LoanStreet as a leading U.S. platform in loan participations/secondary loan trading, citing a large registered-institution footprint for this niche.

Product Line Growth: The platform has expanded beyond matchmaking into execution, servicing, reporting, and analytics, with newer launches such as CECL reporting and corporate/commercial loan servicing indicating continued suite broadening.

Investor Backing & Capital Strength: A disclosed $25M Series B provides a tangible capital base to fund product investment and go-to-market execution in a regulated B2B workflow category.